Takeda Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Co., Ltd.

Overview
Date Founded

1781

Headquarters

1-1, Doshomachi 4-chome, Chuo-ku Osaka, 540-8645, Japan

Type of Company

Public

Employees (Worldwide)

29.9K

Industries

Pharmaceuticals
IT Consulting & Services
Hospitals & Patient Services
Medical Support Services
Chemicals
Biotechnology

Company Description

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Executives & Employees

President & Chief Executive Officer

Executive Officer & Global General Counsel

Director Chief Medical & Scientific Officer

General Manager, Health Innovation Park-Shonan

President, Europe & Canada Business Unit

President, US Business Unit

Director President, Japan Pharma Business Unit

President, Global Oncology Business Unit

President, EUCAN Business Unit

President, Emerging Markets Business Unit

Subscribe now to see full list of current and former executives
Advisory Board

Former Chief Executive Officer at Eli Lilly & Company

Subscribe now to see full list of current and former board members
Paths to Takeda Pharmaceutical Co., Ltd.
Potential Connections via
Relationship Science
You
Takeda Pharmaceutical Co., Ltd.
Owners & Shareholders
Details Hidden

NAM-J is an active, value-oriented manager with a global perspective and a medium- to long-term outlook. Their investment philosophy emphasizes multi-faceted research shared internationally throughout the group, and local expertise contributed by their overseas offices. Their strong research capabilities, supported and integrated globally by proprietary systems, include fundamental analysis, company visits, market research, credit analysis, macroeconomic projections and quantitative analysis. Their global asset allocation strategy is determined by an investment committee at the group level.The firm uses a variety of strategies including active, passive and active quantitative. Their funds are invested in domestic and global equity and fixed-income, as well as in Japanese money market instruments. The majority of their investments are in equity, complemented by a substantial minority of bonds and investments in private placement funds. The firm manages a range of Japanese ETFs including sector funds.NAM-J's investment process is team-based and combines bottom-up and top-down strategies, with a bias towards stockpicking.

Details Hidden

Daiwa AM is an active, mid-to long-term manager which seeks to identify hidden values which are not yet fully recognized in the market through a balanced approach emphasizing fundamental and quantitative analysis. They conduct in-house research and have a strong global research network.The firm’s basic assumption is that the market is not fully efficient and they employ a coherent investment process through organizational support at each phase of their 'Plan', 'Do' and 'Review' policy. They pursue stable excess mid-to long-term returns through suitable risk control, which they separate from investment management to ensure that the risk control system adequately monitors their investment process. Daiwa AM’s research team analysts and portfolio managers discuss, evaluate and communicate market events and investment opinions, seeking to maximize portfolio performance. Company visits are important components of their bottom-up research process and are a primary source for their fundamental analysis.

Details Hidden

Causeway Capital Management (CCM) specializes in managing investments in international and global value equities. Their strategies include: international value equity, international value select, global value equity, emerging markets equity, international opportunities, global opportunities and global absolute return. In addition, CCM manages ADR, socially responsible and concentrated versions of some of their strategies. The strategies primarily invest in international and US equity securities using fundamental value and quantitative investment techniques. In the global absolute return strategy, the firm also uses leverage and total return equity swap agreements to take long and short positions in equity securities. CCM may also directly sell securities short in the global absolute return strategy.

Subscribe now to see full details
Recent Transactions
Details Hidden

Takeda Pharmaceutical Co., Ltd. purchases TiGenix NV

Details Hidden

Takeda Pharmaceutical Co., Ltd. purchases Tesaro, Inc. /Niraparib drug business from TESARO, Inc.

Details Hidden

Baring Private Equity (Asia) Pte Ltd., Bushu Pharmaceuticals Ltd. purchase Spera Pharma, Inc. from Takeda Pharmaceutical Co., Ltd.

Subscribe now to see full list of recent transations
Transaction Advisors
Investment Advisor

Advised onTakeda Pharmaceutical Co., Ltd. purchases Takeda Pharmaceuticals International GmbH from Credit Suisse Group AG, aPriori Capital Partners LP, Coller Capital Ltd., Nordic Capital V Ltd., Avista Capital Partners, Nordic Capital VI Ltd., Coller International Partners IV LP, Coller International Partners V LP

Investment Advisor

Advised onCaraco Pharmaceutical Laboratories Ltd., Sun Pharmaceutical Industries Ltd. purchase URL Pharma, Inc. /Generic Business from Takeda Pharmaceutical Co., Ltd.

Legal Advisor

Advised onPRA Health Sciences, Inc. purchases Takeda Pharmaceutical Data Services Ltd. from Takeda Pharmaceutical Co., Ltd.

Subscribe now to see 23+ more transaction advisors
Legal Advisor

Advised onTakeda Pharmaceutical Co., Ltd. purchases Takeda Oncology Co.

Legal Advisor

Advised onTakeda Pharmaceutical Co., Ltd. purchases Takeda Pharmaceuticals International GmbH from Credit Suisse Group AG, aPriori Capital Partners LP, Coller Capital Ltd., Nordic Capital V Ltd., Avista Capital Partners, Nordic Capital VI Ltd., Coller International Partners IV LP, Coller International Partners V LP

Attorney

Advised onTakeda Pharmaceutical Co., Ltd. purchases Takeda Oncology Co.

Subscribe now to see 47+ more transaction advisors
Advisors & Consultants
Subscribe now to see advisors & consultants for over 2.5 million organizations
Advisor

Co-Founder at Outpost Medicine LLC

Legal Advisor

Managing Director & General Counsel at BDT Capital Partners LLC

Legal Advisor

Partner at Latham & Watkins LLP

Subscribe now to see 6+ more consultants & advisors
Clients

The Bill & Melinda Gates Foundation was formed in 1997 as the William H. Gates Foundation. In 1999, the foundation was renamed the Bill & Melinda Gates Foundation. The Bill & Melinda Gates Foundation Trust was created in January 2000 through the merger of the Gates Learning Foundation, which worked to expand access to technology through public libraries and the William H. Gates Foundation, which focused on improving global health. The foundation participates in preventive approaches and collaborative endeavors with government, philanthropic and not-for-profit partners. Priority is given to grants that leverage additional support and serve as a catalyst for long-term, systemic change. The foundation also provides funds to promote greater equity in global health, education and public libraries. Through their partnerships in communities across the US, the Bill & Melinda Gates Foundation is committed to raising the high school graduation rate and helping all students, regardless of race or family income. The foundation is headquartered in Seattle, Washington.

Taisho Pharmaceutical Holdings Co. Ltd. engages in the management and administration of its group companies that manufactures and sells pharmaceutical products. It operates through the following segments: Self-Medication, Prescription Pharmaceutical, and Others. The Self-Medication segment conducts research and development (R&D), manufacturing and sales of over-the-counter drugs, quasi-drugs, food, and general medical and hygiene supplies. The Prescription Pharmaceutical segment handles R&D, manufacturing, and sales of ethical drugs. The Others segment consists of the firm's pure holding company operations. The company was founded on October 3, 2011 and is headquartered in Tokyo, Japan.

AbbVie, Inc. is a research-based biopharmaceutical company. It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products. The company focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on January 1, 2013 and is headquartered in North Chicago, IL.

Subscribe now to see 17 more clients
Subscribe now to see clients for over 2.5 million organizations
Key Stats and Financials As of 2017
Market Capitalization
$4.79T
Total Enterprise Value
$4.99T
Earnings Per Share
$147.15
Revenue
$1.73T
Net Profit
$115B
EBITDA
$302B
EBITDAMargin
17.42%
Total Debt
$1.2T
Total Equity
$1.95T
Enterprise Value Sales
2.88x
Enterprise Value EBITDAOperating
16.54x
TEVNet Income
43.43x
Debt TEV
0.24x
Three Year Compounded Annual Growth Rate Of Revenue
0.79%
Five Year Compounded Annual Growth Rate Of Revenue
2.8%
Subscribe now to see full financial details
Investments
Details Hidden

Ovid Therapeutics, Inc. is a biopharmaceutical company, which focuses on developing impactful medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Details Hidden

Cerevance LLC develops novel therapeutics for neurological and psychiatric disorders. The company is headquartered in Cambridge, MA.

Details Hidden

Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Subscribe now to see full investment details
Suppliers
Alnylam Pharmaceuticals, Inc. Medical Support Services | Wilmington, DE

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

XOMA Corp. Pharmaceuticals | Berkeley, California

XOMA Corp. engages in the discovery and development of innovative therapeutics derived from unique platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Berkeley, CA.

Aska Pharmaceutical Co., Ltd. Retail: Drug Stores | Tokyo, TY

ASKA Pharmaceutical Co., Ltd. engages in the manufacture, sale, import and export of pharmaceuticals,veterinary medicines,quasi-drugs,foods,and medical devices. It operates through the following business division: Research and Development. The Research and Development division provides new medicine in R&D system with a balanced combination of cutting-edge pharmaceutical technology and a long experience, to grow and expand persistently as a medium R&D company focusing on a specialized field. Its products include drugs for internal medicine; drugs for obstetrics and genecology; and drugs for urology. The company was founded by Yasohachi Yamaguchi on June 16, 1920 and is headquartered in Tokyo, Japan.

Subscribe now to see 17 more suppliers